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Hyperpolarized 13C‑glucose 
magnetic resonance highlights 
reduced aerobic glycolysis in vivo 
in infiltrative glioblastoma
Mor Mishkovsky1*, Olga Gusyatiner2,3, Bernard Lanz1, Cristina Cudalbu4, Irene Vassallo2,3, 
Marie‑France Hamou2,3, Jocelyne Bloch2,3, Arnaud Comment5, Rolf Gruetter1,4,6,7 & 
Monika E. Hegi2,3*
Glioblastoma (GBM) is the most aggressive brain tumor type in adults. GBM is heterogeneous, with 
a compact core lesion surrounded by an invasive tumor front. This front is highly relevant for tumor 
recurrence but is generally non‑detectable using standard imaging techniques. Recent studies 
demonstrated distinct metabolic profiles of the invasive phenotype in GBM. Magnetic resonance (MR) 
of hyperpolarized 13C‑labeled probes is a rapidly advancing field that provides real‑time metabolic 
information. Here, we applied hyperpolarized 13C‑glucose MR to mouse GBM models. Compared to 
controls, the amount of lactate produced from hyperpolarized glucose was higher in the compact 
GBM model, consistent with the accepted “Warburg effect”. However, the opposite response was 
observed in models reflecting the invasive zone, with less lactate produced than in controls, implying 
a reduction in aerobic glycolysis. These striking differences could be used to map the metabolic 
heterogeneity in GBM and to visualize the infiltrative front of GBM.
Glioblastoma (GBM) is the most common malignant primary brain tumor in adults, notorious for its resistance 
to multimodal therapy with a median survival of less than 2  years1. GBMs are characterized by genetic and mor-
phologic intra-tumoral  heterogeneity2, and consist of a core lesion—often with central necrosis—surrounded 
by an invasive tumor front that is pivotal for tumor  recurrence3. Within the standardized recommendations for 
imaging brain  tumors4, the central mass can be detected by  T2-weighted magnetic resonance imaging (MRI) 
and is highlighted in post-contrast  T1-weighted  image5. The infiltrative front, characterized by a low density of 
invading cells that have migrated into a region with an intact blood–brain barrier (BBB), is in contrast usually 
indiscernible with these standard MRI techniques. Consequently, part of it may lie outside of the resected and 
treated area following surgery and radiation therapy.
Metabolic imaging techniques can offer additional and essential information for the assessment of tumoral 
 tissue6. Because upregulated glycolysis and the associated increase in lactate production (Warburg Effect) is 
considered a hallmark of  cancer7,8, glucose is the substrate of choice for metabolic imaging. Various techniques 
are available to study in vivo glucose metabolism non-invasively, giving complementary information on the 
metabolic pathways of glucose. The widely employed positron emission tomography (PET) of 18F labeled fluoro-
deoxyglucose (18F-FDG)9,10 is limited to detect the total glucose consumption, without distinguishing between 
the tracer and its phosphorylated form, and cannot directly inform on the metabolic pathways subsequent 
to glucose phosphorylation. Moreover, the physiologic glucose consumption in the normal brain generates a 
high background uptake of 18F-FDG, which is generally high in the gray matter, and moderate to high in the 
white matter, thus limiting its application for the detection of brain  tumors11. Magnetic resonance spectroscopy 
(MRS) of non-hyperpolarized (i.e. thermally polarized) metabolites allows to study brain tumor metabolism 
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non-invasively and with non-ionizing  radiation12,13. Metabolite concentrations that were quantified from 1H 
MRS spectra were found to be changing in response to treatment and the metrics describing these characteris-
tics are associated with survival. Moreover, metabolic abnormalities can be detected in the normal-appearing 
brain regions, emphasizing the potential of molecular imaging to visualize the infiltrative  front14,15. Nonetheless, 
despite recent developments, the applicability of these techniques with clinical diagnostics is still challenging. 
Good quality 1H MRS spectrum requires high magnetic field homogeneity, and the measurement of the steady-
state metabolite concentrations provides no direct information on metabolic fluxes. The dynamic measurements 
of non-hyperpolarized (i.e. thermally polarized) 13C MRS can bring kinetic information, but its low sensitivity 
necessitates long acquisition times and long infusion times.
MR detection of hyperpolarized (HP) endogenous compounds, on the other hand, using dissolution dynamic 
nuclear polarization (dDNP)16 can provide real-time metabolic information related to enzymatic  activity17. The 
use of HP substrates has given important insights into GBM  metabolism18–21. In particular, MRS imaging of 
hyperpolarized [1-13C] pyruvate has been shown as a promising technique to monitor metabolism in various 
clinical  studies22,23 including brain tumor  patients24–26. HP pyruvate experiments are limited to probe a specific 
portion of the tumor glucose metabolism. The pyruvate bypasses the glucose transporters by entering the cell via 
the monocarboxylate transporters (MCTs) and then exchanges its 13C label with the endogenous lactate  pools27, 
providing a tool for lactate  topography22. A recent metabolic study in a model representing the infiltrative front 
of GBM indicated a reduction in glucose uptake in the infiltrative GBM model as determined by PET, while the 
metabolic rate of glucose oxidation (CMRglc) quantified by non-hyperpolarized 13C MRS was not significantly 
 reduced28. Hence, direct detection of tumor glycolysis may provide new insights.
The possibility to directly monitor tumor glycolysis using hyperpolarized 13C labeled glucose has been dem-
onstrated in a lymphoma mouse model in vivo29. We have recently reported the real-time detection of cer-
ebral de novo synthesis of [1-13C]lactate following the infusion of HP  [2H7,13C6]d-glucose in  mice30. Therefore, 
the aim of this study was to demonstrate the feasibility to monitor real-time metabolism of hyperpolarized 
 [2H7,13C6]d-glucose in GBM mouse models and to employ this technique to further investigate the metabolic 
fate of glucose in the infiltrative zone of GBM of patient-derived xenografts in mice. We aimed to address the 
question of whether changes in glucose metabolism can be characterized by measuring the de novo lactate 
production through glycolysis, and whether these can delineate differences between the invasive zone of GBM 
from the normal brain by real-time detection of glycolysis.
Results
Implantation of the U87GM cell line (model 1) yielded a compact tumor. A contrast-enhancing ring around a 
necrotic core can be readily observed in the post-contrast  T1-weighted images, indicative of BBB disruption. 
Histology confirmed the observations of a compact tumor in the MRI images (Fig. 1). The patient-derived LN-
2669GS (model 2) and LN-3708GS (model 3) sphere lines gave rise to diffusely invading tumors without visible 
modifications of the brain structure, and were characterized by lack of a focal mass, and absence of enhancement 
Figure 1.  Axial slices of  T2‐weighted images and  T1-weighted images post injection of gadolinium contrast 
agent. The arrows indicate the injected hemisphere. As expected, implantation of U87GM cells lead to 
the development of a focal tumor as confirmed by hematoxylin and eosin (H&E) staining (model 1). 
Immunochemistry for human Nucleolin (hNCL) that detects human cells, visualizing the highly invasive 
properties in the injected and the contra‐lateral side in models 2 and 3, injected with LN-2669GS and 
LN-3708GS, respectively. NCH numbers indicate the identification number of each individual mouse.
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after gadolinium injection. Human tumor cells, visualized by immunostaining for human nucleolin, displayed 
highly invasive features, infiltrating also the contralateral hemisphere (Fig. 1).
Metabolic profiling of tumor models. The metabolite concentrations derived from the 1H spectra 
resulted in distinct metabolic profiles of the tumor models as compared to the contralateral hemisphere and 
their corresponding controls (Fig. 2). The changes in cerebral metabolite concentrations enabled us to monitor 
the development of the infiltrative tumors post cell implantation and to sense cell migration to the contralateral 
hemisphere (Supporting Information Figure 1). In all three examined GBM models, the tumor tissue showed 
an increase in the concentration of total choline (tCho) metabolites that are related to membrane degradation 
and cell proliferation. The putative neuronal marker tNAA showed decreasing concentrations in all developing 
tumors of the injected hemispheres as well as in the contralateral hemispheres of the mice injected with the 
highly infiltrative model 2. The lactate pool size increased in model 1 in the area of the compact tumor mass but 
did not change in the infiltrative GBM models i.e. models 2 and 3 (Fig. 2).
Real‑time measurement of hyperpolarized glucose metabolism. The infusion of HP  [2H7,13C6] 
glucose led to the production of [1-13C] lactate. The area under the curve (AUC) of [1-13C] lactate (183.5 ppm), 
[1-13C]α-glucose (92.9 ppm), and [1-13C]β-glucose (96.8 ppm) were quantified using VNMRJ software by inte-
grating the sum of the 13C MRS spectra after phase and baseline correction. The lactate-to-glucose ratio (LGR) 
between the [1-13C] lactate signal and the sum of [1-13C] α- and β-glucose was calculated. The exact concentra-
tion of the glucose at the infusate solution was determined by high-resolution 13C NMR as previously  proposed31. 
To account for the difference between animals and variances in infusate concentrations post dissolution, we mul-
tiplied those ratios by the actual concentration of the injected HP glucose divided by the animal blood volume, 
resulting in a corrected-LGR (cLGR) as previously  described32. As anticipated, in the well characterized U87GM 
model (model 1) the [1-13C] lactate signals were higher in the tumor bearing brains compared to their controls, 
with the calculated the cLGR being 29% higher (p = 0.009) in the tumor bearing mice. Interestingly, an opposite 
trend was observed in the infiltrative GBM models 2 and 3, in which the signals of [1-13C] lactate after the HP 13C 
glucose bolus were smaller than in their corresponding healthy controls, respectively. The cLGR were reduced by 
65% and 48% in the infiltrative models 2 and 3, respectively, as compared to their controls (Fig. 3). This differ-
ence was significant in model 3 (p = 0.001), however did not reach statistical significance in model 2 (p = 0.113). 
Figure 2.  The steady-state concentrations of lactate, total choline (tCho) and total N-acetylaspartate (tNAA) 
concentrations at the day of HP glucose infusion. Localized 1H spectra were acquired in an 8 μL voxel, located 
in the cell injected hemisphere, as designated by the white square in the image (red spectra), corresponding 
voxel in the contralateral hemisphere (not shown) and in similar voxel in control animals (black spectra). 
The presented concentrations are only from the animals that received the HP 13C glucose bolus. In black are 
concentrations in the medium injected hemisphere in controls (control 1–3). In red, are concentrations in the 
tumor cell injected hemisphere (tumor 1–3), and in the blue concentrations in the contralateral hemisphere 
(contra 1–3) respectively, The number of ‘*’ represent statistically significant levels of p = 0.05, 0.01, 0.005, 0.001, 
0.0005 and 0.00005. NCH numbers indicate the identification number of each individual mouse.
4
Vol:.(1234567890)
Scientific Reports |         (2021) 11:5771  | https://doi.org/10.1038/s41598-021-85339-7
www.nature.com/scientificreports/
The latter may be due to the small number of mice, and the slightly lower 13C fractional enrichment of glucose 
in the control 2 animals (Supporting Information Figure 3). Note that blood glycemia and 13C glucose fractional 
enrichment that may influence these ratios were kept similar for all different measurements, and showed no 
significant differences between the groups (Supporting Information Figure 3).
Discussion
Recent ex vivo and in vivo studies have shown evidences for distinct metabolic profiles associated with the 
invasive phenotype in GBM, indicating active glucose oxidation in human  GBM28,33. In this work, we applied, 
for the first time, HP 13C labeled-glucose to further investigate glucose metabolism in GBM xenograft models in 
the mouse. The cLGR calculated from this measurement is connected to the rate of glucose uptake and real-time 
lactate production through  glycolysis29,30. We examined three GBM models, two representing the infiltration 
zone (models 2 and 3), and are similar to the ones studied by Lai et al.28, and the U87GM model that leads to the 
formation of focal GBM mass (model 1). The latter is a well-characterized GBM model and was employed in this 
study to validate the reliability of the metabolic information detected by the cLGR from the HP glucose MRS. 
Namely, U87GM forms hypoxic  tumors34, as such, hypoxia-induced factor 1 (HIF1) activates genes involved in 
extracellular glucose import and thus stimulating glycolytic energy  production35,36. This was previously visual-
ized by hyperintensity in 18F-FDG  imaging37 and an increase in the endogenous lactate pool-size34,38 (Fig. 2). The 
HP 13C glucose MRS detection of a significantly higher cLGR in brains of U87GM mice (model 1) compared to 
control (control 1) was thus consistent (Fig. 3, + 29%, p = 0.009), and is in accordance with the metabolic shift 
anticipated by the so-called ‘Warburg Effect’7,8. Moreover, this higher labeling of lactate is consistent with previous 
studies with HP [1-13C]pyruvate in the U87GM tumor model that showed a high level of [1-13C]lactate  labeling39.
Interestingly, in models 2 and 3, which reflect the infiltration zone of GBM, we found a different behavior 
of the cLGR. In model 3 the cLGR in the tumor bearing mice was significantly lower than in the corresponding 
controls (− 48%, p = 0.001), and in model 2 the same trend was observed (− 65%) without reaching statistical 
significance. Based on the cLGR values we found that de novo synthesis of lactate as detected by HP glucose 
MRS, was actually lower in the brains of mice implanted with the infiltrative models compared to their corre-
sponding healthy controls. This indicates a reduction of aerobic glycolysis in infiltrative GBM, thus showing an 
Figure 3.  In vivo 13C magnetic resonance spectroscopy (MRS) of hyperpolarized glucose. (A–C) Characteristic 
summed spectra measured from the different tumor models over both hemispheres (red) and the corresponding 
controls (black) following a bolus of hyperpolarized (HP)  [2H7,13C6] d-glucose (A–C). Spectra are normalized 
to their maximal glucose signal, respectively. In all acquisitions [1-13C] d-glucose-β (96.8 ppm), [1-13C] 
d-glucose-α (92.9 ppm) and [1-13C] Lactate (183.5 ppm) were detected. The broad peak at 175 ppm (designated 
by a star) is an impurity in the  [2H7,13C6] d-glucose powder. (D–F) A comparison cLGR revealed an increase 
in the cLGR in model 1 compared to its control, and a decrease of the cLGR in infiltrative models (2 and 3) 
compared to the corresponding controls. cLGRs are normalized to the maximum cLGR observed in each pair to 
account for the differences in animals’ stains and age between the groups (Supporting Information Table 1). For 
all the measurements, we calculated blood glycaemia of 20.2 ± 3.6 mM and fractional enrichment of 13C glucose 
was 53.8 ± 10.2%, with no significant differences between the groups (Supporting Information Figure 3). NCH 
numbers indicate the identification number of each individual mouse.
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opposite trend to what would be expected by the so-called ‘Warburg effect’. Previous work on patient-derived 
GBM models, has reported on a link between 13C labelling of lactate from a HP [1-13C] pyruvate bolus and 
c-Myc  expression40. Upregulation of c-Myc may result in upregulation of GLUT1, MCT1, HK, and LDHA, 
thus one could anticipate a higher lactate labeling from both HP [1-13C] pyruvate and HP 13C glucose under 
c-Myc  upregulation41. In light of that, lower lactate labelling from the HP glucose may be related to lower c-Myc 
expression in the infiltrative models studied in the present work. However further investigations are necessary 
to confirm this hypothesis. Moreover, in these tumors, the endogenous lactate pool size was similar to controls, 
in line with the absence of hypoxic conditions, as we have previously  reported28. In addition, the labeling of 
[3-13C] lactate, after continuous infusion of thermally polarized [1,6-13C2] glucose, was similar in the infiltrative 
tumor model as compared to the control  brain28. One could anticipate a similar response to a long infusion of 
thermally polarized [6,6′-2H2]  glucose42,43. Thus the discrepancy between the lactate pool size and lactate labeling 
emphasizes the unique contrast one can detect with HP 13C glucose MRS, which enables monitoring the net 
13C lactate production. It is likely that the reduction in the cLGR observed here, is a consequence of a decrease 
in the uptake of glucose. The present results support the work of Lai et al. on similar infiltrative GBM models, 
which indicated a reduction in glucose uptake as determined by 18F-FDG PET imaging, while the metabolic rate 
of glucose oxidation (CMRglc) quantified by 13C MRS was not significantly  reduced28. Moreover, recent studies 
with HP pyruvate reported that although the lactate pool does play a role in the hyperpolarized lactate  signal27, 
the pyruvate transport via MCT is of a major role in the detection of downstream metabolites post HP pyruvate 
bolus in some  tumors44–46. A further step would be to examine perhaps a similar outcome might be possible with 
HP 13C-pyruvate in the infiltrative models investigated here. Of note, in the summed spectra of all the different 
models investigated in this study, we could only detect the resonances of the infused HP glucose and the pro-
duced lactate (Supporting Information Figure 4). Nonetheless, we cannot exclude the possibility that HP glucose 
was directed to the pentose phosphate pathway (PPP) to sustain proliferation by the production of amino acids, 
thus resulting in a reduction in the de novo synthesis of 13C labelled lactate. It is likely that the sensitivity of the 
current approach of using HP glucose can be further improved by optimal sample  formulation21 or utilization 
of specifically labelled  glucose30, and may lead to the observation of additional metabolites that could shed light 
on the metabolic pathway involved in the observed reduction in aerobic glycolysis.
The global acquisition strategy employed in this study probably led to an underestimation of the differences 
between the tumor metabolism of HP glucose in the brains implanted with U87GM tumor cells and respective 
mock injected control brains. The global detection scheme employed here confounds the possibility to define the 
metabolic response solely of the tumor tissue. The sensitive area under the coil likely was not only composed of 
tumor tissue (Supporting Information Figure 2). However, even using this somewhat limited detection mode, 
all measured parameters are coherent with what is anticipated by the Warburg effect in this well-characterized 
model. A localized detection scheme would indeed be preferable, and would enable discrimination between 
the tumor and the surrounding brain, and would eventually yield even more pronounced differences. For the 
infiltration models (models 2 and 3), the tumor cells diffused in the brain tissue (Fig. 1), hence the limitation 
in localization is inherent to these models, consequently, a localized detection would lead to a similar result to 
what we observed here by the global detection scheme.
Despite limitations of our acquisition strategy and the restricted number of animals, our results provide proof-
of-principle evidence for the possibility of using HP  [2H7,13C6] d-glucose to monitor lactate production in brain 
tumors. The need for novel techniques to visualize the invasive front of glioblastoma is well established. Here 
we demonstrate that the amount of freshly synthetized [1-13C] lactate produced after exogenous HP  [2H7,13C6] 
d-glucose bolus is increased in the compact GBM tumor model, but decreased in the infiltrative GBM models 
as compared to their respective controls. Although technical challenges need to be overcome before introducing 
the cLGR in diagnostic imaging as a metabolic contrast and in particular limitations related to the short lifetime 
of the hyperpolarized state of glucose, it brings the potential to visualize the infiltrative front of GBM, display-
ing hyperintensity in the compact tumor part and hypointensity at the infiltrative front, a compartment highly 
relevant for tumor recurrence. Recent developments around photo-induced radicals have opened opportunities 
to reduce the delay between preparation and injection of hyperpolarized substrates, possibly allowing translation 
of hyperpolarized 13C-glucose47–49.
Conclusion
We applied for the first time HP glucose MRS to study glucose metabolism in brain tumors, and found a reduc-
tion in aerobic glycolysis in a GBM model representing the infiltrative zone, in opposition to what is expected 
by the ‘Warburg effect’.
Methods and materials
Animal experimentation. Experiments were performed according to the Swiss law for the protection of 
animals and were approved by the Veterinary Office of the Canton de Vaud (Service de la consommation et des 
affaires vétérinaires, VD1181.6, VD2777, and VD3266). All experiments were conducted according to federal 
and local ethical laws and complied with the ARRIVE guidelines. Mice were given free access to food and water 
and were maintained in a 12 h light–dark cycle in a temperature- and humidity-controlled animal facility.
Orthotopic mouse glioma xenograft models. To evaluate the metabolic performance of HP glucose 
MRS, the well-characterized U87GM GBM model was employed. U87 cells  (105), obtained from ATCC, were 
stereotactically injected into the left hemispheres of immunodeficient mice. This model will be referred to as 
model 1. To model the infiltrative compartment of GBM, the patient-derived glioblastoma sphere lines (GS) 
LN-2669GS (clone 822, n = 2; clone 867, n = 1)50,51 and LN-3708GS were stereotactically injected into the left 
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hemispheres of immunodeficient mice as previously described  (105 cells in 5 μL Hank’s Balanced Salt Solution, 
HBSS)52, and will be referred to as Model 2 and 3, respectively. The GS lines were established in the laboratory 
with written consent of the patients (protocol F25/99, approved by the local ethics committee), and authen-
ticated together with the original tumors using short tandem repeats (STR) (Dr. Vincent Castella, University 
Center of Legal Medicine, Lausanne, Switzerland). The corresponding controls (i.e. control 1, 2, and 3) were 
orthotopically injected with 5 μL of the cell suspension solution (HBSS) solely. All mice were 6 weeks old at the 
time of cell implantation. The age at the final HP 13C MRS measurement was dependent on the latency of tumor 
development and varied between the three models. Overall, 31 mice we employed in this study, among them 18 
mice were injected with tumor cells and 13 mice were injected with the cell medium for control. Baseline infor-
mation for the different groups is summarized in Supplementary Table 1.
Hyperpolarization. HP of 13C-labelled glucose was prepared as previously  described30. Briefly, 
[1,2,3,4,5,6,6-2H7, U-13C6]d-glucose (Sigma Aldrich) was dissolved in a polarization medium containing trityl 
radical OX63 (tris{8-carboxyl-2,2,6,6-benzo(1,2-d:5-d)-bis(1,3)dithiole-4-yl-methyl sodium salt) as a polarizing 
agent (ALBEDA, Denmark) dissolved in deionized water with 1:1.1 (w/w) ratio, to yield 3 M glucose and 25 mM 
OX63 radical solution. Frozen beads of the solution where dynamically polarized in a custom-designed 7 T 
DNP polarizer operating at 197 GHz/1.00 ± 0.05  K53 for 3 h, and then rapidly dissolved in 5 mL of superheated 
 D2O and transferred within 2 s into the separator/infusion  pump54, which was prepositioned inside the magnet 
bore. A bolus of the solution was then automatically infused through a vein catheter (see below) to the mouse 
as previously  described31.
Animal preparation for magnetic resonance scans. Mice were longitudinally scanned to monitor 
tumor development. Tumor bearing or control mice were anesthetized using 1.5 ± 0.5% isoflurane (Attane, Min-
rad, NY, USA) in 60% oxygen using a facemask. The anesthetized animals were then transferred to an MRI bed, 
and their head was fixed using a stereotaxic system and a bite bar (RAPID Biomedical Inc., OH, USA). Animal 
physiology was monitored during the entire duration of the experiment. Body temperature was monitored by a 
nonmagnetic rectal probe and maintained at 37.0 ± 0.5 °C by warming the animal with temperature-controlled 
water circulation (SA instruments Inc. NY, USA). The respiration rate was monitored using a pneumatic pillow 
sensor (SA Instruments Ins. Stony Brook, NY, USA).
Mice were selected for the HP glucose experiment when their physiology (i.e. weight loss), as well as MRI 
images and/or metabolites concentration from the MRS spectra indicated presence of a tumor (evolution of 
some metabolites in infiltrative models is presented in Supporting Information Figure 1). At the day of the HP 
glucose experiment, the anesthetized animals were cannulated. In experiments with models and controls 1 and 
3, the catheter was positioned in the femoral vein. In experiments with model 2 and corresponding control 2, 
the tail vein was catheterized to deliver hyperpolarized glucose solution. After mice were transferred to the MRI 
bed, blood glycaemia levels were measured from blood samples (5 μL) collected from the tip of the tail (Breeze2 
glucose meter, Bayer, France), and the animals was entered into the MR scanner.
All MR measurements were carried out on a Varian INOVA spectrometer (Agilent, Palo Alto, CA, USA) 
interfaced with a 31-cm horizontal-bore actively shielded 9.4 T magnet (Magnex Scientific, Abingdon, UK).
In vivo 1H magnetic resonance imaging and spectroscopy. To confirm the presence of tumor we 
searched for morphological modifications  (T2W images) and/or changes in the neurochemical profiles (local-
ized 1H MRS). Spectra were acquired every second week starting 4 weeks post cell implantation. Measurements 
were performed using a home-built 1H-quadrature surface coil that was placed on top of the mouse head.  T2W 
images were acquired using a fast spin echo multi slice (FSEMS) protocol (FOV 18 × 18   mm2, TR = 4000 ms, 
effective TE = 52  ms, 6 scans).  B0 inhomogeneity was corrected using the FASTESTMAT  algorithm55 in two 
2 × 2 × 2 mm voxels, one located in the cell injection area, and the other one located in the corresponding area 
of the contralateral hemisphere. The positioning of the tumor voxel was guided by the location of the scar that 
was formed post cell implantation. Cells were injected at the same coordinates relative to the Bregma by means 
of a stereotactic frame, thus, this voxel is always located at the same general position. The contralateral voxel 
was taken as the mirror image of the tumor voxel. 1H MRS measurements were acquired using SPECIAL pulse 
 sequences56 (TR = 4000 ms, TE = 2.8 ms, 200 ms acquisition time in 15 × 16 scans). Absolute metabolite concen-
trations were calculated using LC  Model57.
The integrity of the blood–brain barrier (BBB) was assessed only on the day of the final experiment by  T1 
weighted  (T1W) imaging post-injection of gadolinium contrast agent gadolinium (Gd3+) dihydroxy-hydroxym-
ethylpropyl-tetraazacyclododecane-triacetic acid (Gadovist, Bayer Pharmaceuticals, France, 5 μL/g body weight). 
This procedure was done after the completion of the HP 13C MRS measurements, using FSEMS pulse-sequence 
(FOV 18 × 18  mm2, TR = 350 ms, effective TE = 11 ms, 6 averages).
In vivo hyperpolarized 13C MRS. 13C MR measurements were performed using a home-built 
1H-quadrature/13C-single loop surface coil that was positioned on top of the mouse head. To improve the detec-
tion within the sensitive area of the 13C coil (Supporting Information Figure 2),  B0 inhomogeneity was corrected 
using FASTESTMAP  algorithm55 in a 135 μL voxel. A 540 μL of 59 ± 17 mM HP  [2H7,13C6]d-glucose was injected 
through a vein catheter by the automated  protocol31. A series of pulse acquired sequences was then triggered 
5.5 s post injection every 0.5 s for 50 s. Frequency selective Gaussian pulse (250 μs) was centered at 182 ppm 
resulting an average nominal 20° flip-angle of the C1 lactate resonance (183.5 ppm) and 1.4° flip-angle on the 
glucose C1 resonances (92.9 ppm and 96.8 ppm) as previously  proposed30. The area under the curve (AUC) 
of [1-13C] lactate (183.5 ppm), [1-13C]α-glucose (92.9 ppm), and [1-13C]β-glucose (96.8 ppm) were quantified 
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using VNMRJ software by integrating the sum of the 13C MRS spectra after phase and baseline correction. Over-
all, 13 tumor mice, and 13 control mice received the HP glucose bolus (model 1, n = 5; control 1, n = 5; model 2, 
n = 3; control 2, n = 3; model 3, n = 5; control 3, n = 5).
Histology and immunohistochemistry. Brains were fixed in formalin (4% buffered formalin), and 
embedded in paraffin. Coronal sections were stained by H&E (haematoxylin and eosin) or immunostained for 
human nucleolin (hNCL, 1:200, 4 °C, overnight; ab13541, Abcam, Cambridge, UK; does not react with mouse) 
to visualize the human GBM cells using a heat antigen retrieval procedure as previously  described58.
Statistical analysis. Statistical analyses were performed using the OriginPro 9.3G software. One-way anal-
ysis of variance (1-way ANOVA) was used followed by Fisher’s test to find significance in the difference between 
each tumor and its corresponding control. A p value of 0.05 was considered significant. All data are presented as 
means ± standard deviation unless otherwise stated.
Data availability
All data is available from the corresponding authors upon reasonable request.
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